Medicine background
Tesamorelin
A GHRH analogue with a specific US licensed medical use.
Also discussed as: EGRIFTA
THE RESEARCH QUESTION
What is being investigated?
The US label concerns excess abdominal fat in adults with HIV-associated lipodystrophy. It does not authorise general weight loss or longevity use.
EVIDENCE SNAPSHOT
US approval for a specific indication
An indication-specific approval cannot be extended to healthy people seeking body-composition changes. US approval does not establish UK authorisation.
LIMITS & SAFETY
What should you know?
Label concerns include glucose changes, raised IGF-I, fluid retention and malignancy-related contraindications.
FOLLOW THE EVIDENCE
Sources & further reading
- DailyMed: EGRIFTA WR (tesamorelin) prescribing information ↗US medicine label
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.